CU24603B1 - Imidazopirimidinas diazabicíclicas sustituidas útiles en el tratamiento de trastornos respiratorios - Google Patents

Imidazopirimidinas diazabicíclicas sustituidas útiles en el tratamiento de trastornos respiratorios

Info

Publication number
CU24603B1
CU24603B1 CU2019000101A CU20190101A CU24603B1 CU 24603 B1 CU24603 B1 CU 24603B1 CU 2019000101 A CU2019000101 A CU 2019000101A CU 20190101 A CU20190101 A CU 20190101A CU 24603 B1 CU24603 B1 CU 24603B1
Authority
CU
Cuba
Prior art keywords
imidazopyrimidines
useful
treatment
respiratory disorders
substituted diazabicyclic
Prior art date
Application number
CU2019000101A
Other languages
English (en)
Other versions
CU20190101A7 (es
Inventor
Dr Udo Albus
Dr Moritz Beck-Broichsitter
Dr Karl Collins
Dr Martina Delbeck
Doris Gehring
Dr Michael Hahn
Niels Lindner
Dr Klemens Lustig
Dr Thomas Müller
Dr Janine Nicolai
Björn Rosenstein
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of CU20190101A7 publication Critical patent/CU20190101A7/es
Publication of CU24603B1 publication Critical patent/CU24603B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La presente solicitud se refiere a imidazopirimidinas diazabicíclicas sustituidas de fórmula I:</p> <p>ESPACIO PARA LA FÓRMULA</p> <p>,útiles en el tratamiento de trastornos respiratorios. Se refiere también a los procedimientos de preparación de las mismas.</p>
CU2019000101A 2017-06-14 2018-06-07 Imidazopirimidinas diazabicíclicas sustituidas útiles en el tratamiento de trastornos respiratorios CU24603B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17176046 2017-06-14
EP17193252 2017-09-26
PCT/EP2018/064977 WO2018228907A1 (de) 2017-06-14 2018-06-07 Diazabicyclisch substituierte imidazopyrimidine und ihre verwendung zur behandlung von atemstörungen

Publications (2)

Publication Number Publication Date
CU20190101A7 CU20190101A7 (es) 2020-10-20
CU24603B1 true CU24603B1 (es) 2022-06-06

Family

ID=62492660

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2019000101A CU24603B1 (es) 2017-06-14 2018-06-07 Imidazopirimidinas diazabicíclicas sustituidas útiles en el tratamiento de trastornos respiratorios

Country Status (36)

Country Link
US (3) US11098063B2 (es)
EP (1) EP3638675B1 (es)
JP (2) JP6896113B2 (es)
KR (1) KR102364134B1 (es)
CN (4) CN115554299A (es)
AR (1) AR112099A1 (es)
AU (1) AU2018283331B2 (es)
BR (1) BR112019026450A2 (es)
CA (1) CA3066942A1 (es)
CL (1) CL2019003650A1 (es)
CO (1) CO2019014047A2 (es)
CR (1) CR20190563A (es)
CU (1) CU24603B1 (es)
DO (1) DOP2019000308A (es)
EA (1) EA202090043A1 (es)
EC (1) ECSP19088492A (es)
ES (1) ES2985167T3 (es)
GE (2) GEP20227366B (es)
HR (1) HRP20240678T1 (es)
HU (1) HUE066512T2 (es)
IL (1) IL271117B (es)
JO (1) JOP20190284A1 (es)
MA (1) MA49368B1 (es)
MX (2) MX2019014983A (es)
MY (1) MY204293A (es)
NI (1) NI201900126A (es)
NZ (1) NZ758821A (es)
PE (1) PE20200016A1 (es)
PH (1) PH12019502828A1 (es)
PL (1) PL3638675T3 (es)
RS (1) RS65543B1 (es)
SG (1) SG11201911508XA (es)
TW (1) TWI801388B (es)
UA (1) UA125186C2 (es)
UY (1) UY37773A (es)
WO (1) WO2018228907A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180088462A (ko) 2015-12-10 2018-08-03 바이엘 파마 악티엔게젤샤프트 수면-관련 호흡기 장애의 치료를 위한 TASK-1 및 TASK-2 채널의 차단제로서의 2-페닐-3-(피페라지노메틸)이미다조[1,2-a]피리딘 유도체
JOP20190284A1 (ar) 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
WO2018227427A1 (en) 2017-06-14 2018-12-20 Bayer Aktiengesellschaft Substituted bridged diazepane derivatives and use thereof
WO2020225185A1 (en) * 2019-05-09 2020-11-12 Bayer Aktiengesellschaft COMBINATION OF AN α2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA
CA3139298A1 (en) 2019-05-09 2020-11-12 Bayer Aktiengesellschaft Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea
AU2020377470A1 (en) 2019-11-06 2022-05-26 Bayer Aktiengesellschaft Inhibitors of adrenoreceptor ADRAC2
KR20230035349A (ko) 2020-07-06 2023-03-13 바이엘 악티엔게젤샤프트 수면 무호흡의 치료를 위한 알파2-아드레날린수용체 하위유형 c (알파-2c) 길항제와 task1/3 채널 차단제의 조합물
GB202101734D0 (en) * 2021-02-08 2021-03-24 Cerevance Inc Novel Compounds
CN118434415A (zh) 2021-12-22 2024-08-02 拜耳公司 用于治疗睡眠呼吸暂停的task1/3通道阻断剂与毒蕈碱型受体拮抗剂的结合物
MX2024007764A (es) 2021-12-22 2024-07-04 Bayer Ag Combinacion de un bloqueante de canales task1/3 con un inhibidor de la recaptacion de norepinefrina para el tratamiento de la apnea del sue?o.
US20250057845A1 (en) 2021-12-22 2025-02-20 Bayer Aktiengesellschaft Combination of a task1/3 channel blocker with a p2x3 receptor antagonist for the treatment of sleep apnea
AU2023205312A1 (en) 2022-01-07 2024-07-25 Ocular Therapeutix, Inc. 2,3-dihydrobenzo [b][1, 4]dioxin-2-ylmethyl)piperazin-1-yl derivates for the treatment of sleep apnea
CN118785902A (zh) 2022-01-07 2024-10-15 拜耳公司 用于治疗睡眠呼吸暂停的α2-肾上腺素受体亚型C拮抗剂
WO2025068514A1 (en) 2023-09-28 2025-04-03 Bayer Aktiengesellschaft Substituted heterocyclic carboxamindes and use thereof
CN117959293B (zh) * 2024-01-18 2025-05-13 香港大学深圳医院 非奈利酮在制备治疗和/或预防卵巢功能障碍疾病药物中的应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
MY125533A (en) * 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
AU2001270297A1 (en) 2000-06-30 2002-01-14 Neurogen Corporation 2-phenylimidazo(1,2-a)pyridine derivatives: a new class of gaba brain receptor ligands
GB0017256D0 (en) 2000-07-13 2000-08-30 Merck Sharp & Dohme Therapeutic agents
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
SE0100568D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE10247269A1 (de) 2002-10-10 2004-04-22 Grünenthal GmbH Substituierte C-Imidazo[1,2-a]pyridin-3-yl-methylamine
US7855194B2 (en) 2006-03-27 2010-12-21 Hoffmann-La Roche Inc. Pyrimidine, quinazoline, pteridine and triazine derivatives
KR101390239B1 (ko) * 2006-04-27 2014-04-30 사노피-아벤티스 도이칠란트 게엠베하 Ｔａｓｋ-1 및 ｔａｓｋ-3 이온 채널 억제제
EP2049110B1 (en) 2006-07-14 2014-08-20 Merck Sharp & Dohme Corp. Bridged diazepan orexin receptor antagonists
EP1974729A1 (en) 2007-03-28 2008-10-01 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists
CA2724842A1 (en) 2008-05-19 2009-11-26 Sunovion Pharmaceuticals Inc. Imidazo[1,2-a]pyridine compounds
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
ES2572387T3 (es) 2010-03-18 2016-05-31 Pasteur Institut Korea Compuestos anti-infecciosos
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
PH12013500055A1 (en) 2010-07-09 2017-08-23 Bayer Ip Gmbh Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
CN103298468A (zh) 2011-02-01 2013-09-11 协和发酵麒麟株式会社 稠环杂环衍生物
EP2691392A1 (en) 2011-03-31 2014-02-05 EMBLEM Technology Transfer GmbH Imidazo [1,2-a]pyridine compounds for use in therapy
KR102104125B1 (ko) 2011-04-21 2020-05-29 재단법인 한국파스퇴르연구소 소염 화합물
WO2013037736A1 (en) 2011-09-12 2013-03-21 Sanofi Indanyl-substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
WO2013037914A1 (en) * 2011-09-16 2013-03-21 Sanofi Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
EP2755973B1 (en) 2011-09-16 2015-11-04 Sanofi Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
ES2623167T3 (es) 2012-02-03 2017-07-10 Sanofi Pirroldicarboxamidas condensadas y su uso como productos farmacéuticos
WO2014187922A1 (en) * 2013-05-24 2014-11-27 Iomet Pharma Ltd. Slc2a transporter inhibitors
SI3122750T1 (sl) 2014-03-26 2019-12-31 F. Hoffmann-La Roche Ag Biciklične spojine kot zaviralci proizvodnje avtotaksina (ATX) in lizofosfatidne kisline (LPA)
JP2018012645A (ja) 2014-11-26 2018-01-25 持田製薬株式会社 新規ジアザビシクロ誘導体
WO2016085784A1 (en) 2014-11-26 2016-06-02 Merck Sharp & Dohme Corp. Methyl diazepane orexin receptor antagonists
TWI585785B (zh) * 2014-11-26 2017-06-01 Murata Manufacturing Co Electronic parts manufacturing methods, electronic components and electronic devices
WO2016085783A1 (en) 2014-11-26 2016-06-02 Merck Sharp & Dohme Corp. Bridged diazepane orexin receptor antagonists
JP2018016544A (ja) 2014-12-03 2018-02-01 持田製薬株式会社 新規ジアザビシクロ［２．２．２］オクタン誘導体
CN107635995B (zh) 2015-09-24 2022-08-19 豪夫迈·罗氏有限公司 作为atx抑制剂的二环化合物
KR20180088462A (ko) * 2015-12-10 2018-08-03 바이엘 파마 악티엔게젤샤프트 수면-관련 호흡기 장애의 치료를 위한 TASK-1 및 TASK-2 채널의 차단제로서의 2-페닐-3-(피페라지노메틸)이미다조[1,2-a]피리딘 유도체
WO2017097671A1 (de) 2015-12-10 2017-06-15 Bayer Pharma Aktiengesellschaft Substituierte perhydropyrrolo[3,4-c]pyrrol-derivate und ihre verwendung
JOP20190005A1 (ar) * 2016-07-20 2019-01-20 Bayer Ag مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها
JOP20190148A1 (ar) 2016-12-21 2019-06-18 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية
JOP20190141A1 (ar) 2016-12-21 2019-06-12 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي
JOP20190284A1 (ar) * 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
WO2018227427A1 (en) 2017-06-14 2018-12-20 Bayer Aktiengesellschaft Substituted bridged diazepane derivatives and use thereof
GEP20247606B (en) 2018-11-27 2024-03-11 Bayer Ag Process for producing pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
WO2020225185A1 (en) 2019-05-09 2020-11-12 Bayer Aktiengesellschaft COMBINATION OF AN α2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA
CA3139298A1 (en) 2019-05-09 2020-11-12 Bayer Aktiengesellschaft Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea

Also Published As

Publication number Publication date
CR20190563A (es) 2020-04-22
TW201919638A (zh) 2019-06-01
MX2019014983A (es) 2020-02-24
PL3638675T3 (pl) 2024-07-01
CN115554299A (zh) 2023-01-03
AU2018283331A1 (en) 2019-12-19
CU20190101A7 (es) 2020-10-20
ES2985167T3 (es) 2024-11-04
CN110719911B (zh) 2022-10-21
KR102364134B1 (ko) 2022-02-18
JP2020523388A (ja) 2020-08-06
RS65543B1 (sr) 2024-06-28
ECSP19088492A (es) 2019-12-27
US12180227B2 (en) 2024-12-31
EP3638675A1 (de) 2020-04-22
DOP2019000308A (es) 2020-01-31
AU2018283331B2 (en) 2022-08-04
CN115583959A (zh) 2023-01-10
US20200109155A1 (en) 2020-04-09
US20250154175A1 (en) 2025-05-15
PE20200016A1 (es) 2020-01-06
EP3638675C0 (de) 2024-04-17
MA49368B1 (fr) 2024-06-28
CL2019003650A1 (es) 2020-07-10
EA202090043A1 (ru) 2020-04-02
GEP20227366B (en) 2022-03-25
CN115554300B (zh) 2024-10-29
JP6896113B2 (ja) 2021-06-30
MX2022012716A (es) 2022-11-07
CN110719911A (zh) 2020-01-21
CN115583959B (zh) 2024-04-26
MY204293A (en) 2024-08-21
IL271117A (en) 2020-01-30
CN115554300A (zh) 2023-01-03
JP2021127346A (ja) 2021-09-02
IL271117B (en) 2022-03-01
AR112099A1 (es) 2019-09-18
TWI801388B (zh) 2023-05-11
KR20200014915A (ko) 2020-02-11
UA125186C2 (uk) 2022-01-26
MA49368A (fr) 2021-04-14
NI201900126A (es) 2020-04-02
HUE066512T2 (hu) 2024-08-28
GEAP202115256A (en) 2021-10-11
UY37773A (es) 2019-01-02
HRP20240678T1 (hr) 2024-08-16
NZ758821A (en) 2025-05-02
CO2019014047A2 (es) 2020-01-17
JOP20190284A1 (ar) 2019-12-11
BR112019026450A2 (pt) 2020-07-14
EP3638675B1 (de) 2024-04-17
US20220017540A1 (en) 2022-01-20
CA3066942A1 (en) 2018-12-20
WO2018228907A1 (de) 2018-12-20
SG11201911508XA (en) 2020-01-30
US11098063B2 (en) 2021-08-24
PH12019502828A1 (en) 2020-10-26

Similar Documents

Publication Publication Date Title
CU24603B1 (es) Imidazopirimidinas diazabicíclicas sustituidas útiles en el tratamiento de trastornos respiratorios
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
NI201800128A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
NI201700095A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
CR20160523A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
MX375970B (es) Compuestos de triazolopirimidina y usos de los mismos.
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
UY35274A (es) Compuestos y métodos para tratar infecciones bacterianas
DOP2020000072A (es) Amidas de imidazopiridina sustituidas y su uso
EA201600434A1 (ru) Применение производных бензимидазолпролина
GT201700058A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
CL2015003195A1 (es) Derivados de purina como agonistas del receptor cb2.
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
CR20160016A (es) Pirazolpiridinas sustituidas
UY36851A (es) Compuestos para uso en aplicaciones antibacterianas
CL2017003025A1 (es) Derivados(1,2-b)(1,2,4)de imidazotriazina como agentes antiparasitarios.
CU20180044A7 (es) Derivados novedosos de diamino piridina
AR095353A1 (es) Compuesto
CL2017002148A1 (es) Derivados de tetrahidropiranil benzamida
NI201500172A (es) Composiciones farmacéuticas
BR112015030589A8 (pt) formas polimórficas de fosfato de icotinibe, composição farmacêutica compreendendo as referidas formas e usos das mesmas